Serial #79399473
LIVE

Serial Number

79399473

Owner

Bicycletx Limited

Attorney

Christina M. Licursi

Filing Date

May 2, 2024

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79399473 Trademark

Serial Number: 79399473 • Registration: 7954011

Serial #79399473 is a trademark filed by Bicycletx Limited on May 2, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Bicycletx Limited (33 trademarks)

Blocks A & B Portway Building,

Entity Type: 99

Trademark Details

Filing Date

May 2, 2024

Registration Date

September 23, 2025

Published for Opposition

August 5, 2025

Goods & Services

Medical services; medical testing for diagnostic or treatment purposes; healthcare services; pharmaceutical services, namely, pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in connection with respiratory disease; medical services in connection with cardiovascular disease; medical services in connection with metabolic disease; medical services in connection with the treatment and/or prevention of viral infections; medical services in connection with diagnostics and imaging; medical services in connection with renal disease; medical services in connection with gastrointestinal disease; medical services in connection with muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti- infectives; pharmaceutical compounding services in connection with respiratory disease; pharmaceutical compounding services in connection with cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid

Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; medical research services, namely, industrial analysis and research services in the field of medicine; pharmaceutical research and development services; medical research and development services; pharmaceutical research services, namely, pharmaceutical testing and clinical trials; scientific research in the nature of conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of medical diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; scientific research consulting, namely, providing information consultancy and advisory services relating to the aforesaid in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents

Pharmaceuticals for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the treatment of cancer; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and prevention of respiratory disease; pharmaceutical products and preparations for the treatment and prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and prevention of renal disease; pharmaceutical products and preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and prevention of muscular skeletal disease

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 16, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 1, 2026 FICS
FINAL DISPOSITION PROCESSED
Mar 31, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 25, 2025 OPNX
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 23, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 10, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 10, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 23, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 23, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 5, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 5, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 30, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 30, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 26, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 26, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 26, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 26, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 2, 2025 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 26, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 26, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 26, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 26, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 26, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 26, 2025 COAR
REFUSAL PROCESSED BY IB
Jan 17, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 2, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jan 2, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 11, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 10, 2024 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Dec 10, 2024 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 26, 2024 RFCR
NON-FINAL ACTION WRITTEN
Nov 25, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 16, 2024 DOCK
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 19, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 19, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 19, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 19, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 19, 2024 COAR
APPLICATION FILING RECEIPT MAILED
Jul 12, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 12, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 11, 2024 REPR